KR100686364B1 - 패혈증 치료에 사용하기 위한 면역흡착제 - Google Patents

패혈증 치료에 사용하기 위한 면역흡착제 Download PDF

Info

Publication number
KR100686364B1
KR100686364B1 KR1020017012230A KR20017012230A KR100686364B1 KR 100686364 B1 KR100686364 B1 KR 100686364B1 KR 1020017012230 A KR1020017012230 A KR 1020017012230A KR 20017012230 A KR20017012230 A KR 20017012230A KR 100686364 B1 KR100686364 B1 KR 100686364B1
Authority
KR
South Korea
Prior art keywords
immunosorbent
antibody
specific
bound
lps
Prior art date
Application number
KR1020017012230A
Other languages
English (en)
Korean (ko)
Other versions
KR20010112371A (ko
Inventor
하인리히한스-베르너
한한스-유르겐
마이어우도
크루쉬케페터
바그너하인츠-유르겐
Original Assignee
비오제르프 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비오제르프 아게 filed Critical 비오제르프 아게
Publication of KR20010112371A publication Critical patent/KR20010112371A/ko
Application granted granted Critical
Publication of KR100686364B1 publication Critical patent/KR100686364B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Anesthesiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020017012230A 1999-03-26 2000-03-23 패혈증 치료에 사용하기 위한 면역흡착제 KR100686364B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19913707.2 1999-03-26
DE19913707A DE19913707A1 (de) 1999-03-26 1999-03-26 Immunadsorber zur Sepsistherapie

Publications (2)

Publication Number Publication Date
KR20010112371A KR20010112371A (ko) 2001-12-20
KR100686364B1 true KR100686364B1 (ko) 2007-02-23

Family

ID=7902471

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017012230A KR100686364B1 (ko) 1999-03-26 2000-03-23 패혈증 치료에 사용하기 위한 면역흡착제

Country Status (13)

Country Link
US (1) US6881408B1 (de)
EP (1) EP1163004B1 (de)
JP (1) JP4307743B2 (de)
KR (1) KR100686364B1 (de)
CN (1) CN1160126C (de)
AT (1) ATE233571T1 (de)
AU (1) AU760668B2 (de)
CA (1) CA2366455C (de)
DE (2) DE19913707A1 (de)
ES (1) ES2193958T3 (de)
HK (1) HK1044115A1 (de)
IL (1) IL145557A (de)
WO (1) WO2000058005A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829085B2 (en) 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
DE10118446A1 (de) * 2001-04-12 2002-10-17 Thomas Hartung Prüfverfahren zur Untersuchung fließfähiger Medien auf Gehalte an mikrobiellen Toxinen
US20030215460A1 (en) * 2002-05-07 2003-11-20 Schall Thomas J. Methods and compositions for inducing an immune response
EP1575507A2 (de) * 2002-04-02 2005-09-21 Scantibodies Laboratory, Inc. Verfahren und vorrichtungen zur behandlung von schweren peripheren bakteriellen infektionen
EP2266606B1 (de) * 2003-05-15 2014-09-10 Genentech, Inc. Verfahren und Zubereitungen zur Prävention und Behandlung von Blutvergiftung
EP1706079B1 (de) 2003-08-14 2013-02-20 ThromboGenics N.V. Antikörper gegen faktor viii mit modifizierter glykosilierung in der variablen region
WO2005084198A2 (en) * 2004-02-27 2005-09-15 Vaxconsulting Peptides of il1 beta and tnf alpha and method of treatment using same
DE102004029573A1 (de) * 2004-06-18 2005-12-29 Gambro Lundia Ab MIF-Adsorbent
ITMI20041569A1 (it) * 2004-07-30 2004-10-30 Tecnogen Scpa "ligandi peptidici specifici per le immunoglobuline"
US20080255344A1 (en) * 2004-10-20 2008-10-16 Hans-Werner Heinrich Immuno-Adsorbers For Treatment of Inflammations
WO2007013945A2 (en) * 2005-07-20 2007-02-01 The Regents Of The University Of California Treating disorders associated with inflammation
WO2007024825A2 (en) * 2005-08-26 2007-03-01 Genway Biotech, Inc. Immunoaffinity separation and analysis compositions and methods
US8430831B2 (en) 2009-02-25 2013-04-30 The Invention Science Fund I, Llc Device, system, and method for controllably reducing inflammatory mediators in a subject
DE102009034150A1 (de) * 2009-07-20 2011-01-27 Fresenius Medical Care Deutschland Gmbh Adsorbens zur Adsorption von Hepcidin
EP2679302A1 (de) 2012-06-28 2014-01-01 Zentrum für biomedizinische Technologie der Donau- Universität Krems Selektives Sorptionsmittel für die extrakorporale Blutreinigung
EP3185926B1 (de) 2014-08-26 2018-11-28 3M Innovative Properties Company System zur entfernung von proinflammatorischen mediatoren sowie von granulozyten und monozyten aus blut
EP3477300A1 (de) 2017-10-25 2019-05-01 Euroimmun Medizinische Labordiagnostika AG Zellulose-basierter immunadsorber
US20190247560A1 (en) * 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
WO2021063708A1 (en) 2019-09-30 2021-04-08 Hemotune Ag Assembly for extracorporeal treatment of body fluids
CN113967367A (zh) * 2020-07-25 2022-01-25 苏州仝乾医疗科技有限公司 新冠病毒治疗用细胞因子抗体组合物及治疗用吸附剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300740A2 (de) * 1987-07-20 1989-01-25 Cefem A/S Monoklonale Antikörper gegen das Komplement C5A
US5679775A (en) * 1995-04-27 1997-10-21 B. Braun Melsungen Ag. Process and device for the simultaneous extracorporeal elimination of tumour necrosis factor and bacterial lipopolysaccharides from whole blood and/or blood plasma

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8918232D0 (en) * 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock
US5626843A (en) * 1993-02-26 1997-05-06 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS, by removel of interferons, TNFs and receptors therefor
AU680897B2 (en) * 1993-03-16 1997-08-14 Aventis Pharmaceuticals Inc. Removal of selected factors from whole blood or its components and prevention and treatment of septic shock symdrome
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
AU2191795A (en) 1994-03-23 1995-10-09 Alexion Pharmaceuticals, Inc. Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5922690A (en) 1996-04-25 1999-07-13 Van Gorp; Cornelius L. Dermatan disulfate, an inhibitor of thrombin generation and activation
US6287516B1 (en) * 1998-07-10 2001-09-11 Immunocept, L.L.C. Hemofiltration systems, methods, and devices used to treat inflammatory mediator related disease
US6193681B1 (en) * 1998-09-14 2001-02-27 American Immuno Tech, Llc. Septicemia prevention and treatment system

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300740A2 (de) * 1987-07-20 1989-01-25 Cefem A/S Monoklonale Antikörper gegen das Komplement C5A
US5679775A (en) * 1995-04-27 1997-10-21 B. Braun Melsungen Ag. Process and device for the simultaneous extracorporeal elimination of tumour necrosis factor and bacterial lipopolysaccharides from whole blood and/or blood plasma

Also Published As

Publication number Publication date
EP1163004B1 (de) 2003-03-05
WO2000058005A3 (de) 2001-03-29
CN1160126C (zh) 2004-08-04
ATE233571T1 (de) 2003-03-15
DE19913707A1 (de) 2000-10-05
ES2193958T3 (es) 2003-11-16
JP4307743B2 (ja) 2009-08-05
IL145557A0 (en) 2002-06-30
KR20010112371A (ko) 2001-12-20
US6881408B1 (en) 2005-04-19
DE50001376D1 (de) 2003-04-10
CA2366455C (en) 2012-06-05
JP2002539910A (ja) 2002-11-26
WO2000058005A2 (de) 2000-10-05
AU760668B2 (en) 2003-05-22
HK1044115A1 (en) 2002-10-11
CA2366455A1 (en) 2000-10-05
IL145557A (en) 2005-09-25
AU4742500A (en) 2000-10-16
CN1346280A (zh) 2002-04-24
EP1163004A2 (de) 2001-12-19

Similar Documents

Publication Publication Date Title
KR100686364B1 (ko) 패혈증 치료에 사용하기 위한 면역흡착제
Zaoui et al. Effects of dialysis membranes on beta2-mieroglobulin production and cellular expression
JPH04505010A (ja) 免疫調節障害の処置のための薬剤生成物
WO2008089756A2 (de) Verfahren zum nachweis von antikörpern aus körperflüssigkeiten durch eine immunreaktion mit glykoprotein 2 (gp2) aus zymogenen granula des pankreas zur differentialdiagnose von entzündlichen darmerkrankungen und chronischer pankreatitis
CA2490218C (en) Extracorporeal photopheresis in combination with anti-tnf treatment
AU3420689A (en) Method and means for immuno-stimulating blood treatment with a mitogen
WO1996032121A1 (en) Pharmaceutical preparations derived from european mistletoe
US20110174733A1 (en) FILTER SYSTEM FOR EXTRACORPOREAL DEPLETION OF ACTIVATED POLYMORPHONUCLEAR LEUKOCYTES (PMNs)
US20080255344A1 (en) Immuno-Adsorbers For Treatment of Inflammations
AT410636B (de) Verfahren zur herstellung eines impfstoffes
WO2000008463A2 (de) Immunadsorber zur entfernung von endotoxinin
EP1367393A1 (de) Verfahren zur Verwendung des CD 163 Wegs zur Modulation einer Immunantwort
DE102005046258A1 (de) Immunadsorber zur Behandlung von Insulinresistenz und des metabolischen Syndroms
CN1155374C (zh) 丙谷胺的新生物活性
EP0681480B1 (de) Recognin vakzine
Kayes et al. Pulmonary granuloma formation in murine toxocariasis: transfer of granulomatous hypersensitivity using bronchoalveolar lavage cells
RU2283666C9 (ru) Средство для активации восстановления структуры и функции поврежденных тканей и органов
EP1950222A1 (de) Verfahren zum Nachweis von Antikörpern aus Körperflüssigkeiten durch eine Immunreaktion mit Glykoprotein 2 (GP2) aus zymogenen Granula des Pankreas zur Differentialdiagnose von entzündlichen Darmerkrankungen und chronischer Pankreatitis
DE102007004909A1 (de) Verfahren zum Nachweis von Antikörpern aus Körperflüssigkeiten durch eine Immunreaktion mit Glykoprotein 2(GP2) aus zymogenen Granula des Pankreas zur Differentialdiagnose von entzündlichen Darmerkrankungen und chronischer Pankreatitis
Kano Immunoserological and Immunohistological Study on Experimental Glomerulonephritis
MacDonald The role of non-MHC-restricted cytotoxic effector cells in the pathogenesis of acute graft-versus-host disease in F₁-hybrid mice
Holt Vascular endothelial cell dysfunction in systemic sclerosis.
JPH04501258A (ja) 血清免疫調節ポリペプチドおよびその使用法
DE3135124A1 (de) "verfahren zum nachweis maligner neoplasien der weiblichen brustdruese des menschen mit hilfe spezifischer antikoerper gegen die vermutlich verantwortlichen viruspartikel sowie zum nachweis dieser viruspartikel oder ihrer antigene und reagentien zur durchfuehrung des verfahrens"
FR2960882A1 (fr) Co-culture de cellules mononucleees et de cellules mesenchymateuses pour l'obtention de cellules productrices d'il-17

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130328

Year of fee payment: 7

FPAY Annual fee payment

Payment date: 20140211

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee